ReviewTransgenic research2016
The transgenic animal platform for biopharmaceutical production.
Review in Transgenic research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 95 citations in OpenAlex.
- CRISPR/Cas9-mediated targeted knock-in of human erythropoietin at the β-casein locus results in lactogenic hormone-responsive expression in HC11 mammary epithelial cells.Scientific reports · 2026Article
- Transgenesis in Drug Discovery: Enhancing Target Identification and Validation.Molecular biotechnology · 2026Review
- Article
- Proteostasis as a Sentry for Sperm Quality and Male Fertility.Advances in experimental medicine and biology · 2025Review
- Genome editing: An insight into disease resistance, production efficiency, and biomedical applications in livestock.Functional & integrative genomics · 2024Review
- Review
- Article
- Application of Gene Editing Technology in Resistance Breeding of Livestock.Life (Basel, Switzerland) · 2022Review
- Expression of a triple mutational des-pGlu brazzein in transgenic mouse milk.FEBS open bio · 2022Article
- The Improved Milk Quality and Enhanced Anti-Inflammatory Effect in Acetylserotonin-O-methyltransferase (Molecules (Basel, Switzerland) · 2022Article
- Use of Genome Editing Techniques to Produce Transgenic Farm Animals.Advances in experimental medicine and biology · 2022Review
- Recombinant Protein Production and Purification of Insoluble Proteins.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Physiological impact of the environment on the welfare of transgenic goats raised in a tropical climate.International journal of biometeorology · 2021Article
- Biological drug therapy for ocular angiogenesis: Anti-VEGF agents and novel strategies based on nanotechnology.Pharmacology research & perspectives · 2021Review
- Development of a Mucus Gland Bioreactor in LoachInternational journal of molecular sciences · 2021Article
- Recombinant Proteins and Monoclonal Antibodies.Advances in biochemical engineering/biotechnology · 2021Review
- Production of Recombinant Monoclonal Antibodies in the Egg White of Gene-Targeted Transgenic Chickens.Genes · 2020Article
- Evaluating the effect ofJournal of biological research (Thessalonike, Greece) · 2020Article
- Rescue of caprine fetal ovaries, vitrification and follicular development after xenotransplantation in two immunodeficient mice models.Animal reproduction · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recombinant production of therapeutic proteins for human diseases is currently the largest source of innovation in the pharmaceutical industry. The market growth has been the driving force on efforts for the development of new therapeutic proteins, in which transgenesis emerges as key component. The use of the transgenic animal platform offers attractive possibilities, residing on the low production costs allied to high productivity and quality of the recombinant proteins. Although many strategies have evolved over the past decades for the generation of transgenic founders, transgenesis in livestock animals generally faces some challenges, mainly due to random transgene integration and control over transgene copy number. But new developments in gene editing with CRISPR/Cas system promises to revolutionize the field for its simplicity and high efficiency. In addition, for the final approval of any given recombinant protein for animal or human use, the production and characterization of bioreactor founders and expression patterns and functionality of the proteins are technical part of the process, which also requires regulatory and administrative decisions, with a large emphasis on biosafety. The approval of two mammary gland-derived recombinant proteins for commercial and clinical use has boosted the interest for more efficient, safer and economic ways to generate transgenic founders to meet the increasing demand for biomedical proteins worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.